FDA moves to fast-track review of three psychedelic drug studies

The Food and Drug Administration (FDA) connected Friday granted fast-track review to 3 companies studying psychedelic therapies to dainty slump and post-traumatic accent disorder (PTSD), the latest measurement by the Trump medication toward possible approval.  The agency did not disclose the circumstantial companies that were granted priority review vouchers. Two companies are studying psilocybin; one for treatment-resistant depression (TRD) and the different is studying attraction for major depressive disorder.  A 3rd institution is studying methylone, a…